FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:235-242 January 24, 2002 Number 4 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Cheson, B. D. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Methods Previously untreated patients with diffuse large-B-cell lymphoma, 60 to 80 years old, were randomly assigned to receive either eight cycles of CHOP every three weeks (197 patients) or eight cycles of CHOP plus rituximab given on day 1 of each cycle (202 patients).

Results The rate of complete response was significantly higher in the group that received CHOP plus rituximab than in the group that received CHOP alone (76 percent vs. 63 percent, P=0.005). With a median follow-up of two years, event-free and overall survival times were significantly higher in the CHOP-plus-rituximab group (P<0.001 and P=0.007, respectively). The addition of rituximab to standard CHOP chemotherapy significantly reduced the risk of treatment failure and death (risk ratios, 0.58 [95 percent confidence interval, 0.44 to 0.77] and 0.64 [0.45 to 0.89], respectively). Clinically relevant toxicity was not significantly greater with CHOP plus rituximab.

Conclusions The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity.

Source Information

From the Hospices Civils de Lyon and the Université Claude Bernard, Lyons (B.C., G.S.); Hôpital Henri-Mondor, Paris (E.L., P.G., F.R.); Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Paris (J.B., C.G.); Hôpital de Hautepierre, Strasbourg (R.H.); the Centre Becquerel, Rouen (H.T.); the Institut Paoli-Calmette, Marseilles (R.B.); and the Centre Hospitalier de Lens (P.M.) — all in France; and the Université Catholique de Louvain, Brussels, Belgium (E.N.).

Pierre Lederlin, Ph.D., Centre Hospitalier Universitaire de Brabois, Nancy, France, was also an author.

Address reprint requests to Dr. Coiffier at the Service d'Hématologie, Centre Hospitalier Lyon-Sud, 69495 Pierre Bénite CEDEX, France, or at bertrand.coiffier{at}chu-lyon.fr.

Full Text of this Article

Related Letters:

Rituximab plus CHOP for Diffuse Large-B-Cell Lymphoma
Akhtar S., Maghfoor I., Coiffier B., Gisselbrecht C., Reyes F.
Extract | Full Text | PDF  
N Engl J Med 2002; 346:1830-1831, Jun 6, 2002. Correspondence

This article has been cited by other articles:

• Lecuyer, L., Chevret, S., Guidet, B., Aegerter, P., Martel, P., Schlemmer, B., Azoulay, E. (2008). Case volume and mortality in haematological patients with acute respiratory failure. Eur Respir J 32: 748-754 [Abstract] [Full Text]  
• King, J., Waxman, J., Stauss, H. (2008). Advances in tumour immunotherapy. QJM 101: 675-683 [Abstract] [Full Text]  
• Senff, N. J., Noordijk, E. M., Kim, Y. H., Bagot, M., Berti, E., Cerroni, L., Dummer, R., Duvic, M., Hoppe, R. T., Pimpinelli, N., Rosen, S. T., Vermeer, M. H., Whittaker, S., Willemze, R. (2008). European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112: 1600-1609 [Abstract] [Full Text]  
• Klapper, W., Szczepanowski, M., Burkhardt, B., Berger, H., Rosolowski, M., Bentink, S., Schwaenen, C., Wessendorf, S., Spang, R., Moller, P., Hansmann, M. L., Bernd, H.-W., Ott, G., Hummel, M., Stein, H., Loeffler, M., Trumper, L., Zimmermann, M., Reiter, A., Siebert, R., for the "Molecular Mechanisms in Malignant Lymphom, (2008). Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood 112: 1374-1381 [Abstract] [Full Text]  
• Cheson, B. D., Leonard, J. P. (2008). Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma. NEJM 359: 613-626 [Full Text]  
• Raetz, E. A., Cairo, M. S., Borowitz, M. J., Blaney, S. M., Krailo, M. D., Leil, T. A., Reid, J. M., Goldenberg, D. M., Wegener, W. A., Carroll, W. L., Adamson, P. C. (2008). Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. JCO 26: 3756-3762 [Abstract] [Full Text]  
• Tarella, C., Zanni, M., Magni, M., Benedetti, F., Patti, C., Barbui, T., Pileri, A., Boccadoro, M., Ciceri, F., Gallamini, A., Cortelazzo, S., Majolino, I., Mirto, S., Corradini, P., Passera, R., Pizzolo, G., Gianni, A. M., Rambaldi, A. (2008). Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey. JCO 26: 3166-3175 [Abstract] [Full Text]  
• Shimada, K., Matsue, K., Yamamoto, K., Murase, T., Ichikawa, N., Okamoto, M., Niitsu, N., Kosugi, H., Tsukamoto, N., Miwa, H., Asaoku, H., Kikuchi, A., Matsumoto, M., Saburi, Y., Masaki, Y., Yamaguchi, M., Nakamura, S., Naoe, T., Kinoshita, T. (2008). Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan. JCO 26: 3189-3195 [Abstract] [Full Text]  
• Martin, P., Chadburn, A., Christos, P., Furman, R., Ruan, J., Joyce, M. A., Fusco, E., Glynn, P., Elstrom, R., Niesvizky, R., Feldman, E. J., Shore, T. B., Schuster, M. W., Ely, S., Knowles, D. M., Chen-Kiang, S., Coleman, M., Leonard, J. P. (2008). Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 19: 1327-1330 [Abstract] [Full Text]  
• Dillon, R., Hirschfield, G. M, Allison, M. E D, Rege, K. P (2008). Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ 337: a423-a423 [Full Text]  
• Ennishi, D., Takeuchi, K., Yokoyama, M., Asai, H., Mishima, Y., Terui, Y., Takahashi, S., Komatsu, H., Ikeda, K., Yamaguchi, M., Suzuki, R., Tanimoto, M., Hatake, K. (2008). CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 0: mdn392v1-mdn392 [Abstract] [Full Text]  
• Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., Briones, J., Advani, R., Connors, J. M., Byrne, G. E., Levy, R., Gascoyne, R. D., Lossos, I. S. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 111: 5509-5514 [Abstract] [Full Text]  
• Targhetta, C., Cabras, M. G., Mamusa, A. M., Mascia, G., Angelucci, E. (2008). Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. haematol 93: 951-952 [Full Text]  
• Wilson, W. H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S. M., Raffeld, M., Gutierrez, M., Chabner, B. A., Staudt, L., Jaffe, E. S., Janik, J. E. (2008). Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. JCO 26: 2717-2724 [Abstract] [Full Text]  
• Ychou, M., Azria, D., Menkarios, C., Faurous, P., Quenet, F., Saint-Aubert, B., Rouanet, P., Pelegrin, M., Bascoul-Mollevi, C., Guerreau, D., Saccavini, J.-C., Mach, J.-P., Artus, J.-C., Pelegrin, A. (2008). Adjuvant Radioimmunotherapy Trial with Iodine-131-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab')2 after Resection of Liver Metastases from Colorectal Cancer. Clin. Cancer Res. 14: 3487-3493 [Abstract] [Full Text]  
• Persky, D. O., Unger, J. M., Spier, C. M., Stea, B., LeBlanc, M., McCarty, M. J., Rimsza, L. M., Fisher, R. I., Miller, T. P. (2008). Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014. JCO 26: 2258-2263 [Abstract] [Full Text]  
• Crump, M., Coiffier, B., Jacobsen, E. D., Sun, L., Ricker, J. L., Xie, H., Frankel, S. R., Randolph, S. S., Cheson, B. D. (2008). Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19: 964-969 [Abstract] [Full Text]  
• Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., Rice, A. G., van Abbema, A., Wong, M., Liu, G., Zhan, F., Dillon, M., Chen, S., Rhodes, S., Fuh, F., Tsurushita, N., Kumar, S., Vexler, V., Shaughnessy, J. D. Jr., Barlogie, B., van Rhee, F., Hussein, M., Afar, D. E.H., Williams, M. B. (2008). CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma. Clin. Cancer Res. 14: 2775-2784 [Abstract] [Full Text]  
• Canellos, G. P. (2008). What Constitutes "Improved Prognosis"?. JCO 26: 1913-1914 [Full Text]  
• Oldham, R. K., Dillman, R. O. (2008). Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress. JCO 26: 1774-1777 [Full Text]  
• Hoppe, B. S., Moskowitz, C. H., Filippa, D. A., Moskowitz, C. S., Kewalramani, T., Zelenetz, A. D., Yahalom, J. (2008). Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity. JCO 26: 1858-1864 [Abstract] [Full Text]  
• Thieblemont, C., Grossoeuvre, A., Houot, R., Broussais-Guillaumont, F., Salles, G., Traulle, C., Espinouse, D., Coiffier, B. (2008). Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19: 774-779 [Abstract] [Full Text]  
• Zinzani, P. L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G., Castellucci, P., Marchi, E., Farsad, M., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Bacci, F., Pileri, S., Baccarani, M. (2008). A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 19: 769-773 [Abstract] [Full Text]  
• Lenz, G., Davis, R. E., Ngo, V. N., Lam, L., George, T. C., Wright, G. W., Dave, S. S., Zhao, H., Xu, W., Rosenwald, A., Ott, G., Muller-Hermelink, H. K., Gascoyne, R. D., Connors, J. M., Rimsza, L. M., Campo, E., Jaffe, E. S., Delabie, J., Smeland, E. B., Fisher, R. I., Chan, W. C., Staudt, L. M. (2008). Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma. Science 319: 1676-1679 [Abstract] [Full Text]  
• Pulte, D., Gondos, A., Brenner, H. (2008). Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century. Arch Intern Med 168: 469-476 [Abstract] [Full Text]  
• Ellis, M., al-Ramadi, B., Finkelman, M., Hedstrom, U., Kristensen, J., Ali-Zadeh, H., Klingspor, L. (2008). Assessment of the clinical utility of serial {beta}-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57: 287-295 [Abstract] [Full Text]  
• Overman, M. J., Feng, L., Pro, B., McLaughlin, P., Hess, M., Samaniego, F., Younes, A., Romaguera, J. E., Hagemeister, F. B., Kwak, L., Cabanillas, F., Rodriguez, M. A., Fayad, L. E. (2008). The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19: 553-559 [Abstract] [Full Text]  
• Olejniczak, S. H., Hernandez-Ilizaliturri, F. J., Clements, J. L., Czuczman, M. S. (2008). Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression. Clin. Cancer Res. 14: 1550-1560 [Abstract] [Full Text]  
• Czuczman, M. S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J., Hernandez-Ilizaliturri, F. J. (2008). Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels. Clin. Cancer Res. 14: 1561-1570 [Abstract] [Full Text]  
• Ulaner, G. A., Colletti, P. M., Conti, P. S. (2008). B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience. Radiology 246: 895-902 [Abstract] [Full Text]  
• Ryan, G., Martinelli, G., Kuper-Hommel, M., Tsang, R., Pruneri, G., Yuen, K., Roos, D., Lennard, A., Devizzi, L., Crabb, S., Hossfeld, D., Pratt, G., Dell'Olio, M., Choo, S. P., Bociek, R. G., Radford, J., Lade, S., Gianni, A. M., Zucca, E., Cavalli, F., Seymour, J. F. (2008). Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19: 233-241 [Abstract] [Full Text]  
• Doolittle, N. D., Abrey, L. E., Shenkier, T. N., Tali, S., Bromberg, J. E.C., Neuwelt, E. A., Soussain, C., Jahnke, K., Johnston, P., Illerhaus, G., Schiff, D., Batchelor, T., Montoto, S., Kraemer, D. F., Zucca, E. (2008). Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 111: 1085-1093 [Abstract] [Full Text]  
• Natkunam, Y., Farinha, P., Hsi, E. D., Hans, C. P., Tibshirani, R., Sehn, L. H., Connors, J. M., Gratzinger, D., Rosado, M., Zhao, S., Pohlman, B., Wongchaowart, N., Bast, M., Avigdor, A., Schiby, G., Nagler, A., Byrne, G. E., Levy, R., Gascoyne, R. D., Lossos, I. S. (2008). LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. JCO 26: 447-454 [Abstract] [Full Text]  
• Vellenga, E., van Putten, W. L. J., van 't Veer, M. B., Zijlstra, J. M., Fibbe, W. E., van Oers, M. H. J., Verdonck, L. F., Wijermans, P. W., van Imhoff, G. W., Lugtenburg, P. J., Huijgens, P. C. (2008). Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 111: 537-543 [Abstract] [Full Text]  
• Tsimberidou, A. M., Wierda, W. G., Plunkett, W., Kurzrock, R., O'Brien, S., Wen, S., Ferrajoli, A., Ravandi-Kashani, F., Garcia-Manero, G., Estrov, Z., Kipps, T. J., Brown, J. R., Fiorentino, A., Lerner, S., Kantarjian, H. M., Keating, M. J. (2008). Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. JCO 26: 196-203 [Abstract] [Full Text]  
• Sasaki, S., Shikama, N., Koiwai, K., Kadoya, M. (2008). Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment. Jpn J Clin Oncol 38: 43-48 [Abstract] [Full Text]  
• Fenske, D. B., Chonn, A., Cullis, P. R. (2008). Liposomal Nanomedicines: An Emerging Field. Toxicol Pathol 36: 21-29 [Abstract] [Full Text]  
• Young, K. H., Weisenburger, D. D., Dave, B. J., Smith, L., Sanger, W., Iqbal, J., Campo, E., Delabie, J., Gascoyne, R. D., Ott, G., Rimsza, L., Muller-Hermelink, H. K., Jaffe, E. S., Rosenwald, A., Staudt, L. M., Chan, W. C., Greiner, T. C. (2007). Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 110: 4396-4405 [Abstract] [Full Text]  
• Hassan, R., Broaddus, V. C., Wilson, S., Liewehr, D. J., Zhang, J. (2007). Anti Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts. Clin. Cancer Res. 13: 7166-7171 [Abstract] [Full Text]  
• Balducci, L., Al-Halawani, H., Charu, V., Tam, J., Shahin, S., Dreiling, L., Ershler, W. B. (2007). Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim. The Oncologist 12: 1416-1424 [Abstract] [Full Text]  
• Schmitz, N., Dreger, P., Glass, B., Sureda, A. (2007). Allogeneic transplantation in lymphoma: current status. haematol 92: 1533-1548 [Abstract] [Full Text]  
• Oyen, W. J. G., Bodei, L., Giammarile, F., Maecke, H. R., Tennvall, J., Luster, M., Brans, B. (2007). Targeted therapy in nuclear medicine current status and future prospects. Ann Oncol 18: 1782-1792 [Abstract] [Full Text]  
• Yano, H., Ishida, T., Inagaki, A., Ishii, T., Ding, J., Kusumoto, S., Komatsu, H., Iida, S., Inagaki, H., Ueda, R. (2007). Defucosylated Anti CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome. Clin. Cancer Res. 13: 6494-6500 [Abstract] [Full Text]  
• Le Gouill, S., Talmant, P., Touzeau, C., Moreau, A., Garand, R., Juge-Morineau, N., Gaillard, F., Gastinne, T., Milpied, N., Moreau, P., Harousseau, J. L., Avet-Loiseau, H. (2007). The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. haematol 92: 1335-1342 [Abstract] [Full Text]  
• Lee, J.-J., Lam, M. S., Rosenberg, A. (2007). Role of Chemotherapy and Rituximab for Treatment of Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation. The Annals of Pharmacotherapy 41: 1648-1659 [Abstract] [Full Text]  
• Martin, P., Furman, R. R., Coleman, M., Leonard, J. P. (2007). Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma. Clin. Cancer Res. 13: 5636s-5642s [Abstract] [Full Text]  
• Cooney-Qualter, E., Krailo, M., Angiolillo, A., Fawwaz, R. A., Wiseman, G., Harrison, L., Kohl, V., Adamson, P. C., Ayello, J., vande Ven, C., Perkins, S. L., Cairo, M. S. (2007). A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non Hodgkin's Lymphoma: A Children's Oncology Group Study. Clin. Cancer Res. 13: 5652s-5660s [Abstract] [Full Text]  
• Dearden, C. E. (2007). Role of antibody therapy in lymphoid malignancies. Br Med Bull 83: 275-290 [Abstract] [Full Text]  
• Grange, F., Beylot-Barry, M., Courville, P., Maubec, E., Bagot, M., Vergier, B., Souteyrand, P., Machet, L., Dalac, S., Esteve, E., Templier, I., Delaporte, E., Avril, M.-F., Robert, C., Dalle, S., Laroche, L., Delaunay, M., Joly, P., Wechsler, J., Petrella, T. (2007). Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Clinicopathologic Features and Prognostic Analysis in 60 Cases. Arch Dermatol 143: 1144-1150 [Abstract] [Full Text]  
• Oyama, T., Yamamoto, K., Asano, N., Oshiro, A., Suzuki, R., Kagami, Y., Morishima, Y., Takeuchi, K., Izumo, T., Mori, S., Ohshima, K., Suzumiya, J., Nakamura, N., Abe, M., Ichimura, K., Sato, Y., Yoshino, T., Naoe, T., Shimoyama, Y., Kamiya, Y., Kinoshita, T., Nakamura, S. (2007). Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients. Clin. Cancer Res. 13: 5124-5132 [Abstract] [Full Text]  
• Strome, S. E., Sausville, E. A., Mann, D. (2007). A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects. The Oncologist 12: 1084-1095 [Abstract] [Full Text]  
• Chung, R., Lai, R., Wei, P., Lee, J., Hanson, J., Belch, A. R., Turner, A. R., Reiman, T. (2007). Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 110: 1278-1282 [Abstract] [Full Text]  
• Yoong, J. K.-C., Chew, L.-C., Quek, R., Lim, C.-H., Zai, J. Q., Fong, K.-Y., Thumboo, J. (2007). Cardiac lymphoma in primary Sjogren syndrome: A novel case established by targeted imaging and pericardial window. J. Thorac. Cardiovasc. Surg. 134: 513-514 [Full Text]  
• El Gnaoui, T, Dupuis, J, Belhadj, K, Jais, J-P, Rahmouni, A, Copie-Bergman, C, Gaillard, I, Divine, M, Tabah-Fisch, I, Reyes, F, Haioun, C (2007). Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18: 1363-1368 [Abstract] [Full Text]  
• Ponzoni, M., Ferreri, A. J.M., Campo, E., Facchetti, F., Mazzucchelli, L., Yoshino, T., Murase, T., Pileri, S. A., Doglioni, C., Zucca, E., Cavalli, F., Nakamura, S. (2007). Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting. JCO 25: 3168-3173 [Abstract] [Full Text]  
• Armitage, J. O. (2007). How I treat patients with diffuse large B-cell lymphoma. Blood 110: 29-36 [Full Text]  
• Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P. L., Rule, S., Liberati, A. M., Milpied, N., Hess, G., Stein, H., Kalmus, J., Marcus, R. (2007). Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110: 54-58 [Abstract] [Full Text]  
• Herrmann, K., Wieder, H. A., Buck, A. K., Schoffel, M., Krause, B.-J., Fend, F., Schuster, T., Meyer zum Buschenfelde, C., Wester, H.-J., Duyster, J., Peschel, C., Schwaiger, M., Dechow, T. (2007). Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma. Clin. Cancer Res. 13: 3552-3558 [Abstract] [Full Text]  
• Bjorkholm, M, Hagberg, H, Holte, H, Kvaloy, S, Teerenhovi, L, Anderson, H, Cavallin-Stahl, E, Myhre, J, Pertovaara, H, Ost, A, Nilsson, B, Osby, E (2007). Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 18: 1085-1089 [Abstract] [Full Text]  
• Nyman, H., Adde, M., Karjalainen-Lindsberg, M.-L., Taskinen, M., Berglund, M., Amini, R.-M., Blomqvist, C., Enblad, G., Leppa, S. (2007). Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109: 4930-4935 [Abstract] [Full Text]  
• Zhang, M., Yao, Z., Patel, H., Garmestani, K., Zhang, Z., Talanov, V. S., Plascjak, P. S., Goldman, C. K., Janik, J. E., Brechbiel, M. W., Waldmann, T. A. (2007). Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc. Natl. Acad. Sci. USA 104: 8444-8448 [Abstract] [Full Text]  
• Cittera, E., Leidi, M., Buracchi, C., Pasqualini, F., Sozzani, S., Vecchi, A., Waterfield, J. D., Introna, M., Golay, J. (2007). The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab. J. Immunol. 178: 6616-6623 [Abstract] [Full Text]  
• Sehn, L. H., Donaldson, J., Filewich, A., Fitzgerald, C., Gill, K. K., Runzer, N., Searle, B., Souliere, S., Spinelli, J. J., Sutherland, J., Connors, J. M. (2007). Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109: 4171-4173 [Abstract] [Full Text]  
• Thieblemont, C., Coiffier, B. (2007). Lymphoma in Older Patients. JCO 25: 1916-1923 [Abstract] [Full Text]  
• Lenz, H.-J. (2007). Management and Preparedness for Infusion and Hypersensitivity Reactions. The Oncologist 12: 601-609 [Abstract] [Full Text]  
• Hess, P. R., Barnes, C., Woolard, M. D., Johnson, M. D. L., Cullen, J. M., Collins, E. J., Frelinger, J. A. (2007). Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood 109: 3300-3307 [Abstract] [Full Text]  
• Gopal, A. K., Rajendran, J. G., Gooley, T. A., Pagel, J. M., Fisher, D. R., Petersdorf, S. H., Maloney, D. G., Eary, J. F., Appelbaum, F. R., Press, O. W. (2007). High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma. JCO 25: 1396-1402 [Abstract] [Full Text]  
• Rubenstein, J. L., Fridlyand, J., Abrey, L., Shen, A., Karch, J., Wang, E., Issa, S., Damon, L., Prados, M., McDermott, M., O'Brien, J., Haqq, C., Shuman, M. (2007). Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma. JCO 25: 1350-1356 [Abstract] [Full Text]  
• Wohrer, S, Troch, M, Zwerina, J, Schett, G, Skrabs, C, Gaiger, A, Jaeger, U, Zielinski, C., Raderer, M (2007). Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol 18: 647-651 [Abstract] [Full Text]  
• Strobel, K, Schaefer, N., Renner, C, Veit-Haibach, P, Husarik, D, Koma, A., Hany, T. (2007). Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?. Ann Oncol 18: 658-664 [Abstract] [Full Text]  
• Mohammad, R. M., Goustin, A. S., Aboukameel, A., Chen, B., Banerjee, S., Wang, G., Nikolovska-Coleska, Z., Wang, S., Al-Katib, A. (2007). Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1. Clin. Cancer Res. 13: 2226-2235 [Abstract] [Full Text]  
• Verdonck, L. F., Notenboom, A., de Jong, D. D., MacKenzie, M. A., Verhoef, G. E. G., Kramer, M. H. H., Ossenkoppele, G. J., Doorduijn, J. K., Sonneveld, P., van Imhoff, G. W. (2007). Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 109: 2759-2766 [Abstract] [Full Text]  
• Cairo, M. S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C. R., Michon, J., Weston, C., Perkins, S. L., Raphael, M., McCarthy, K., Patte, C., on behalf of the FAB LMB96 International Study Com, (2007). Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109: 2736-2743 [Abstract] [Full Text]  
• Bonnet, C., Fillet, G., Mounier, N., Ganem, G., Molina, T. J., Thieblemont, C., Ferme, C., Quesnel, B., Martin, C., Gisselbrecht, C., Tilly, H., Reyes, F. (2007). CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. JCO 25: 787-792 [Abstract] [Full Text]  
• Ng, A. K., Mauch, P. M. (2007). Role of Radiation Therapy in Localized Aggressive Lymphoma. JCO 25: 757-759 [Full Text]  
• Chiu, G. N.C., Edwards, L. A., Kapanen, A. I., Malinen, M. M., Dragowska, W. H., Warburton, C., Chikh, G. G., Fang, K. Y.Y., Tan, S., Sy, J., Tucker, C., Waterhouse, D. N., Klasa, R., Bally, M. B. (2007). Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Molecular Cancer Therapeutics 6: 844-855 [Abstract] [Full Text]  
• Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., Gascoyne, R. D., Connors, J. M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-1861 [Abstract] [Full Text]  
• Stel, A. J., ten Cate, B., Jacobs, S., Kok, J. W., Spierings, D. C. J., Dondorff, M., Helfrich, W., Kluin-Nelemans, H. C., de Leij, L. F. M. H., Withoff, S., Kroesen, B. J. (2007). Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis. J. Immunol. 178: 2287-2295 [Abstract] [Full Text]  
• Egyed, M., Kollar, B., Prievara, F.T., Viski, A., Bajzik, G., Pajor, L., Torday, L. (2007). Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy. haematol 92: e26-e27 [Abstract] [Full Text]  
• Nitta, E, Izutsu, K, Sato, T, Ota, Y, Takeuchi, K, Kamijo, A, Takahashi, K, Oshima, K, Kanda, Y, Chiba, S, Motokura, T, Kurokawa, M (2007). A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18: 364-369 [Abstract] [Full Text]  
• Arnold, D. M., Dentali, F., Crowther, M. A., Meyer, R. M., Cook, R. J., Sigouin, C., Fraser, G. A., Lim, W., Kelton, J. G. (2007). Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura. ANN INTERN MED 146: 25-33 [Abstract] [Full Text]  
• Sperr, W. R., Lechner, K., Pabinger, I. (2007). Rituximab for the treatment of acquired antibodies to factor VIII. haematol 92: 66-71 [Abstract] [Full Text]  
• Kolstad, A., Holte, H., Fossa, A., Lauritzsen, G. F., Gaustad, P., Torfoss, D. (2007). Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. haematol 92: 139-140 [Abstract] [Full Text]  
• Ramadan, K., Shenkier, T, Sehn, L., Gascoyne, R., Connors, J. (2007). A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 18: 129-135 [Abstract] [Full Text]  
• Bello, C., Sotomayor, E. M. (2007). Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond. ASH Education Book 2007: 233-242 [Abstract] [Full Text]